Showing results (21-30 of 51) with videos related to
Sort By:
Pageof 6
Clinical Science (London, England : 1979)|March 29, 2020
Self DNA perpetuates IPF lung fibroblast senescence in a cGAS-dependent mannerMichael Schuliga, Jane Read, Kaj E C Blokland, et al.American Journal of Physiology. Lung Cellular and Molecular Physiology|September 15, 2021
A cGAS-dependent response links DNA damage and senescence in alveolar epithelial cells: a potential drug target in IPFMichael Schuliga, Amama Kanwal, Jane Read, et al.Tissue Barriers|September 2, 2016
IL-1α mediates cellular cross-talk in the airway epithelial mesenchymal trophic unitAlison R Hill, Jessica E Donaldson, Cornelia Blume, et al.BMC Pulmonary Medicine|January 27, 2018
Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registryHelen E Jo, Ian Glaspole, Yuben Moodley, et al.BMJ Open Respiratory Research|July 20, 2019
Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre studyLauren K Troy, Christopher Grainge, Tamera Corte, et al.American Journal of Respiratory and Critical Care Medicine|December 7, 2020
Cryobiopsy for Identification of Usual Interstitial Pneumonia and Other Interstitial Lung Disease Features. Further Lessons from COLDICE, a Prospective Multicenter Clinical TrialWendy A Cooper, Annabelle Mahar, Jeffrey L Myers, et al.Journal of Cellular and Molecular Medicine|September 27, 2018
Mitochondrial dysfunction contributes to the senescent phenotype of IPF lung fibroblastsMichael Schuliga, Dmitri V Pechkovsky, Jane Read, et al.Respirology (Carlton, Vic.)|March 30, 2019
Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testingAndrew Burgess, Ken Goon, John D Brannan, et al.Respirology (Carlton, Vic.)|August 29, 2017
Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation AustraliaHelen E Jo, Lauren K Troy, Gregory Keir, et al.Thorax|March 22, 2023
Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trialAlex West, Nazia Chaudhuri, Adam Barczyk, et al.Pageof 6